使用 AMC/DCBA 润喉糖快速缓解急性喉咙痛：随机对照试验。,International Journal of Clinical Practice

当前位置： X-MOL 学术 › Int. J. Clin. Pract. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

使用 AMC/DCBA 润喉糖快速缓解急性喉咙痛：随机对照试验。
International Journal of Clinical Practice ( IF 2.2 ) Pub Date : 2009-10-22 , DOI: 10.1111/j.1742-1241.2009.02230.x
D McNally ₁ , M Simpson , C Morris , A Shephard , M Goulder

Affiliation

目的由于一般不推荐使用抗生素治疗急性喉咙痛，因此临床上有效的非处方 (OTC) 治疗替代方案变得越来越重要。本研究旨在确定戊基间甲酚和 2,4-二氯苯甲醇 (AMC/DCBA) 润喉糖 (Strepsils) 在缓解由上呼吸道感染引起的急性喉咙痛方面的镇痛特性。方法患者（n = 310）被随机分配接受 AMC/DCBA 咽喉含片（n = 155）或非药物安慰剂含片（n = 155）。基线评估后，患者在第一次给药后 5 至 20 分钟的 10 个时间点完成三项评级评估。根据需要服用随后的锭剂，并在第 1 天结束时、第一次给药后 24 小时以及第 2 天和第 3 天结束时进行评估。通过比较喉咙痛的严重程度和喉咙痛缓解等级来评估镇痛特性。还评估了吞咽困难和功能障碍评分。结果戊基间甲酚/DCBA 咽喉含片在首次给药后 5 分钟减轻喉咙疼痛，持续 2 小时，并且在 3 天研究期间的所有评估时间点与非药物含片有显着差异。在缓解喉咙痛、缓解吞咽困难和功能障碍评分方面也观察到了类似的显着效果。治疗组之间报告的不良事件没有差异。结论戊基间甲酚/DCBA 润喉糖可提供持续 2 小时的快速镇痛作用，在锭剂溶解后很长时间内仍能持续缓解。

"点击查看英文标题和摘要"

Rapid relief of acute sore throat with AMC/DCBA throat lozenges: randomised controlled trial.

AIM As antibiotics are generally not recommended for the treatment of acute sore throat, the availability of clinically efficacious, over-the-counter (OTC) treatment alternatives is becoming increasingly important. This study was designed to determine the analgesic properties of amylmetacresol and 2,4-dichlorobenzyl alcohol (AMC/DCBA) throat lozenges (Strepsils) in the relief of acute sore throat caused by upper respiratory tract infections. METHODS Patients (n = 310) were randomly assigned to receive AMC/DCBA throat lozenges (n = 155) or non-medicated placebo lozenges (n = 155). After baseline assessments, patients completed three rating assessments at 10 timepoints from 5 to 20 min after first dose. Subsequent lozenges were taken as required, and assessments were made at the end of Day 1, 24 h after first dose, and at the end of Days 2 and 3. Analgesic properties were assessed by comparing severity of throat soreness and sore throat relief ratings. Difficulty in swallowing and functional impairment scores were also assessed. RESULTS Amylmetacresol/DCBA throat lozenges reduced throat soreness at 5 min after first dose, which persisted for 2 h and was significantly different vs. non-medicated lozenges at all assessment timepoints for the duration of the 3-day study. Similar significant effects were observed with sore throat relief, easing of difficulty with swallowing and functional impairment scores. There were no differences in adverse events reported between treatment groups. CONCLUSION Amylmetacresol/DCBA throat lozenges provide rapid analgesic effects that last for 2 h, providing ongoing relief long after the lozenge has dissolved. The superior analgesic effects and improvements in functional impairment scores observed with AMC/DCBA throat lozenges translate into pain relief benefits that are clinically meaningful and are thus a suitable OTC treatment option for patients in the self-management of acute sore throat.

更新日期：2019-11-01

点击分享查看原文

点击收藏

公开下载

阅读更多本刊新发论文本刊介绍/投稿指南